Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma | News Direct

Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma

Poolbeg Pharma PLC
News release by Poolbeg Pharma PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | March 09, 2023 07:53 AM Eastern Standard Time

 

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new report on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), following the release of selected data from its human volunteer LPS challenge trial for lead molecule POLB 001.

 

 

Contact Details

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

project media

Tags

HealthPharmaBiotechLupusClinical Trial